Home >> Tag Archives: SeraCare Life Sciences

Tag Archives: SeraCare Life Sciences

SeraCare releases v2 NGS QC software , 8/17

August 2017—SeraCare Life Sciences launched iQ NGS QC Management v2, data management software that supports whole-workflow data capture from sample preparation to variant calling along with associated reagent and operator data. The software enables laboratories to re-create their QC workflows, set up their critical quality control metrics in the software, and have the data imported automatically using the new iQ Connector API—all to provide real-time insights into performance.

Read More »

Multiplexed inherited cancer reference material, 7/17

July 2017—SeraCare Life Sciences launched the industry’s first multiplexed inherited cancer reference material for inherited disease testing by next-generation sequencing, according to the company. The Seraseq Inherited Cancer DNA Mix reference materials were developed to validate the ability of synthetic reference materials to address technically challenging variants.

Read More »

SeraCare releases v2 NGS QC software

July 5, 2017—SeraCare Life Sciences launched iQ NGS QC Management v2, data management software that supports whole-workflow data capture from sample preparation to variant calling along with associated reagent and operator data. The software enables laboratories to re-create their QC workflows, set up their critical quality control metrics in the software, and have the data imported automatically using the new ...

Read More »

Fusion RNA assay reference standards, 4/17

April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).

Read More »

SeraCare, NIST partner on ctDNA reference materials

Aug. 24, 2016—SeraCare Life Sciences and the U.S. Department of Commerce’s National Institute of Standards and Technology have signed a three-year cooperative research and development agreement to advance the development of circulating-tumor DNA diagnostic assay reference standard materials. SeraCare’s ctDNA reference materials are mixtures of size-appropriate fragments of DNA containing highly multiplexed numbers of somatic driver mutations, produced at very ...

Read More »

SeraCare and NIST partner, 8/16

August 2016—SeraCare Life Sciences and the U.S. Department of Commerce National Institute of Standards and Technology have signed a three-year cooperative research and development agreement (CRADA) to advance the development of circulating tumor DNA diagnostic assay reference standard materials.

Read More »

Biosynthetic reference materials, 6/16

June 2016—SeraCare Life Sciences launched an expanded product line to support NGS-based somatic tumor profiling assay development, validation, and QC performance monitoring. The eight new Seraseq Solid Tumor Mutation Mix-II products contain 40 somatic variants with increases in the number of insertion-deletion mutations from four to 13 to challenge both the sequencing and variant calling algorithms.

Read More »

Solid tumor mutation mix, 9/15

SeraCare Life Sciences’ new precision medicine business unit has launched its first product, the Seraseq Solid Tumor Mutation Mix—I (AF20), a biosynthetic reference material designed to evaluate the performance of next-generation-sequencing–based tumor profiling assays.

Read More »
X